TABUTEAU HERRIOT

CIK 00012199271 companyNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001219927

Recent Transactions

29 trades

Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-04$148.18/sh−10,558→ 7,229 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-04$148.18/sh−10,558→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-04−10,558→ 171,824 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-04$8.02/sh+10,558→ 17,787 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-04$8.02/sh+10,558→ 17,787 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-04−10,558→ 171,824 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-03$8.02/sh+20,163→ 27,392 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-03−20,163→ 182,382 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-03$8.02/sh+20,163→ 27,392 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-03−20,163→ 182,382 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-03$146.94/sh−20,163→ 7,229 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-03$146.94/sh−20,163→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-02$8.02/sh+49,252→ 56,481 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-02$144.59/sh−49,252→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-02−49,252→ 202,545 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-02$8.02/sh+49,252→ 56,481 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-02$144.59/sh−49,252→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-02−49,252→ 202,545 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-16$114.19/sh−19,719→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-09-16−19,719→ 461,120 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-16$8.02/sh+19,719→ 26,948 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-15$8.02/sh+15,254→ 22,483 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-15$117.37/sh−15,254→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-09-15−15,254→ 480,839 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-12$8.02/sh+27,907→ 35,136 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-12$118.96/sh−27,907→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-09-12−27,907→ 496,093 total
Award
Axsome Therapeutics, Inc.$AXSM
Restricted Stock Units
2020-03-17+51,691→ 51,691 total
Award
Axsome Therapeutics, Inc.$AXSM
Employee Stock Option (Right to Buy)
2020-03-17+168,776→ 168,776 total

Companies

Axsome Therapeutics, Inc.
Director, Chief Executive Officer, 10% Owner
$AXSM

Recent Filings

Address

C/O AXSOME THERAPEUTICS, INC. ONE WORLD TRADE CENTER, 29TH FLOOR

NEW YORK, NY, 10007

View on SEC.gov